Business
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\n– New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery –\n\n\n– A retrospective clinical study of the Pressure-Enabled Drug Delivery™ (PEDD™) method supports selection of the TriNav® Infusion System for treatment-refractory hypovascular tumors –\n\n\n DENVER & SALT LAKE CITY--(BUSINESS WIRE)--\nTechnology from TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, was featured in two oral presentations at the Society of Interventional Radiology Annual Scientific Meeting.\n\n\nPERIO-03 Phase 1/1b Update\n\n\nTriSalus is studying an investigational class C toll-like receptor-9 (TLR9) agonist, nelitolimod (formerly SD-101), delivered intravascularly using the Company’s proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method of administration in three Phase 1 trials (periotrial.com). In PERIO-03, nelitolimod is delivered via the PEDD method with the TriSalus Infusion System using a retrograde venous approach, leveraging established interventional radiology access techniques.\n\n\nEarly safety and feasibility data from the PERIO-03 trial for locally advanced pancreatic adenocarcinoma showed technical success in all five patients who had received eight treatment interventions at data cutoff. There were no immediate complications from the procedure, and there was no evidence of hemorrhage or thrombosis. This follows a previous report indicating evidence of encouraging immune signals such as decreases in myeloid derived suppressor cells (MDSC) in the treated pancreatic tumors with evidence of T-cell activation.\n\n\nPEDD Performance in Hypovascular Solid Tumors\n\n\nIn a retrospective study, investigators from The University of Texas MD Anderson Cancer Center reported on a variety of tumor types, the majority of which were notable for being hypovascular metastases and for which embolization may be clinically challenging. Technical success for embolization using the TriNav microcatheter was 100%. Tumors were treated in the liver (88%), bone (9.4%), and adrenal gland (3.1%). Local tumor progression-free survival rates across o...